Veracyte to acquire Allegro Diagnostics Corp for $21 million and with it BronchoGen lung cancer test

Veracyte, Inc. a molecular diagnostics company in the field of molecular cytology, announced an agreement to acquire Allegro Diagnostics Corp, for $21 million. Allegro is a privately held company focused on developing genomic tests to improve the preoperative diagnosis of lung cancer. Veracyte plans to commercially launch Allegro's lead lung cancer test, BronchoGen, in the second half of 2015, with meaningful revenue expected in 2017.